Remove 2017 Remove Drug Development Remove Insurance Coverage and Processing
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. In addition to these issues, further barriers to drug access remain in the UK and US.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field. In addition to these issues, further barriers to drug access remain in the UK and US.

article thumbnail

NHC Comments on Response to the Medicare Program; Request for Information on Medicare Advantage Data

Putting Patients First Blog

1 This trend underscores the importance of informed decision-making for those with chronic diseases and disabilities, who face crucial choices regarding their health care coverage – whether selecting between traditional Medicare and MA, choosing among MA plans, or navigating their selected plan to access necessary care. As of 2023, 30.8